تفاصيل الوثيقة
|
نوع الوثيقة |
: |
مقال في مجلة دورية |
|
عنوان الوثيقة |
: |
HER-2/neu Receptor Status and Non–Small Cell Lung Cancer: is there any Prognostic Correlation? HER-2/neu Receptor Status and Non–Small Cell Lung Cancer: is there any Prognostic Correlation? |
|
لغة الوثيقة |
: |
الانجليزية |
|
المستخلص |
: |
Background: HER-2/neu plays a key role in malignant proliferation of cells in a variety of human tumors. HER-2/neu was found to be over expressed in both cell lines and samples of non-small-cell lung (NSCL). The aim of this study is to examine the predictive and prognostic significance of HER-2/neu among Saudi patients with NSCL cancer .
Patients and Methods: Data of patients with NSCL cancer seen at King Faisal Specialist Hospital and Research Center, Jeddah between March 2000 and March 2004 were retrospectively reviewed. We examined the predictive and prognostic effect of HER-2/neu expression and traditional factors on response and survival.
Results: 53 patients were included in the study. There were 39 (74%), and 14 (26%) males and females, respectively. Median age was 60 years. Disease stage was Stage II (8 patients, 15%), Stage III (13 patients, 25%), and Stage IV (32 patients, 60%). Histopathology showed squamous cell carcinoma (25 patients, 47%), adenocarcinoma (22 patients, 42%), six patients (11%) had other NSCLC histological types. HER-2/neu overexpression (3+) was demonstrated in only three patients (6%), while eight patients (15%) were HER-2/neu +2. Radiation therapy, surgery, chemotherapy and radiation therapy, surgery plus chemo-radiation therapy, chemotherapy, and best supportive care were the primary treatment in 15 (28%), 10 (19%), 10 (19%), 7 (13%), 6 (11%), and 5 (10%) of patients, respectively. Post treatment assessment of response showed complete response, partial response, stable disease, and progressive disease in 11 (21%), 9 (17), 6 (11%), and 18 (34%) of patients, respectively. Response could not be assessed In nine patients (17%),. Her-2/neu showed no predictive effect. Of all patients, 19 of 50 (38%) with negative HER-2/neu (< 3+) showed CR or PR response vs. one of three (33%) of patients with 3+ HER-2/neu (p = 0.68). Over a median follow-up of 10 months, the median survival time was 13.6 months (95% CI: 9.4 – 17.8 months). The difference in survival between patients with Her-2/neu 3+ and Her-2/neu 3- was not significant (p = 0.18).
Conclusion: In this series, Her-2/neu over expressed in a minority of Saudi patients with NSCL. Her-2/neu status showed no predictive or prognostic effect in patients with NSCL cancer. |
|
ردمد |
: |
0749-8063 |
|
اسم الدورية |
: |
Egyptian journal of clinical oncology |
|
المجلد |
: |
1 |
|
العدد |
: |
2 |
|
سنة النشر |
: |
2005 هـ
2005 م |
|
نوع المقالة |
: |
مقالة علمية |
|
تاريخ الاضافة على الموقع |
: |
Sunday, April 11, 2010 |
|
الباحثون
| جودة المغربي | Al-Maghrabi, Jaudah | باحث مشارك | دكتوراه | |
|
الرجوع إلى صفحة الأبحاث
|